Arjang Djamali

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1281052/publications.pdf

Version: 2024-02-01

179	5,825	87888	88630
papers	citations	38	70
		h-index	g-index

179	179	179	6418
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation. Radiology, 2007, 243, 148-157.	7.3	1,273
2	Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis and Tissue Repair, 2012, 5, 7.	3.4	229
3	Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet, The, 2016, 388, 983-993.	13.7	148
4	Assessment of Acute Renal Transplant Rejection with Blood Oxygen Levelâ€“Dependent MR Imaging: Initial Experience. Radiology, 2005, 236, 911-919.	7.3	130
5	Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. American Journal of Physiology - Renal Physiology, 2007, 293, F445-F455.	2.7	112
6	C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation, 2015, 99, 1151-1155.	1.0	111
7	BOLD-MRI assessment of intrarenal oxygenation and oxidative stress in patients with chronic kidney allograft dysfunction. American Journal of Physiology - Renal Physiology, 2007, 292, F513-F522.	2.7	109
8	The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation, 2016, 100, 39-53.	1.0	105
9	Epithelial-to-Mesenchymal Transition and Oxidative Stress in Chronic Allograft Nephropathy. American Journal of Transplantation, 2005, 5, 500-509.	4.7	100
10	Predictors and outcomes of delayed graft function after living-donor kidney transplantation. Transplant International, 2016, 29, 81-87.	1.6	90
11	Medical Care of Kidney Transplant Recipients after the First Posttransplant Year. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 623-640.	4.5	81
12	Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys. Magnetic Resonance Imaging, 2011, 29, 74-82.	1.8	79
13	Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneys. Magnetic Resonance Imaging, 2010, 28, 56-64.	1.8	78
14	Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation, 2019, 103, 1722-1729.	1.0	76
15	Current outcomes of chronic active antibody mediated rejection â€“ A large single center retrospective review using the updated BANFF 2013 criteria. Human Immunology, 2016, 77, 346-352.	2.4	70
16	Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transplant International, 2016, 29, 167-172.	1.6	68
17	Noninvasive Assessment of Early Kidney Allograft Dysfunction by Blood Oxygen Level-Dependent Magnetic Resonance Imaging. Transplantation, 2006, 82, 621-628.	1.0	67
18	Antithymocyte Globulin Is Associated With a Lower Incidence of De Novo Donor-Specific Antibodies in Moderately Sensitized Renal Transplant Recipients. Transplantation, 2014, 97, 612-617.	1.0	67

#	Article	IF	Citations
19	A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal of the American Society of Nephrology: JASN, 2019, 30, 1481-1494.	6.1	67
20	Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney International, 2003, 64, 1800-1807.	5.2	66
21	The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrology Dialysis Transplantation, 2016, 31, 1746-1753.	0.7	63
22	Pretransplant Donor-Specific Antibodies Detected by Single-Antigen Bead Flow Cytometry Are Associated With Inferior Kidney Transplant Outcomes. Transplantation, 2010, 90, 1079-1084.	1.0	62
23	Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. Journal of Clinical Investigation, 2015, 125, 208-221.	8.2	62
24	LOW DOSE ANTITHYMOCYTE GLOBULINS IN RENAL TRANSPLANTATION. Transplantation, 2000, 69, 799-805.	1.0	57
25	Outcomes in kidney transplantation. Seminars in Nephrology, 2003, 23, 306-316.	1.6	56
26	Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrology Dialysis Transplantation, 2005, 20, 1456-1462.	0.7	54
27	Drug Insight: maintenance immunosuppression in kidney transplant recipients. Nature Clinical Practice Nephrology, 2006, 2, 688-699.	2.0	54
28	Reproducibility of renal perfusion MR imaging in native and transplanted kidneys using nonâ€contrast arterial spin labeling. Journal of Magnetic Resonance Imaging, 2011, 33, 1414-1421.	3.4	54
29	Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients1. Transplantation, 2003, 76, 816-820.	1.0	52
30	Comparing Kidney Perfusion Using Noncontrast Arterial Spin Labeling MRI and Microsphere Methods in an Interventional Swine Model. Investigative Radiology, 2011, 46, 124-131.	6.2	47
31	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. Transplantation, 2009, 87, 125-132.	1.0	46
32	CKD stage-to-stage progression in native and transplant kidney disease. Nephrology Dialysis Transplantation, 2007, 23, 693-700.	0.7	45
33	Heat Shock Protein 27 in Chronic Allograft Nephropathy: A Local Stress Response. Transplantation, 2005, 79, 1645-1657.	1.0	44
34	The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model. Fibrogenesis and Tissue Repair, 2010, 3, 1.	3.4	44
35	Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Investigative Radiology, 2016, 51, 701-705.	6.2	41
36	Conversion from Calcineurin Inhibitorâ€“ to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3252-3264.	6.1	41

#	Article	IF	Citations
37	Luminex-Based Desensitization Protocols: The University of Wisconsin Initial Experience. Transplantation, 2011, 92, 12-17.	1.0	40
38	Measurement and comparison of T1 relaxation times in native and transplanted kidney cortex and medulla. Journal of Magnetic Resonance Imaging, 2011, 33, 1241-1247.	3.4	40
39	Utility of protocol kidney biopsies for de novo donor-specific antibodies. American Journal of Transplantation, 2017, 17, 3210-3218.	4.7	40
40	Chronic Kidney Disease Stage Progression in Liver Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1851-1857.	4.5	38
41	Tacrolimus Trough Level at Discharge Predicts Acute Rejection in Moderately Sensitized Renal Transplant Recipients. Transplantation, 2014, 97, 986-991.	1.0	38
42	Longitudinal Assessment of Renal Perfusion and Oxygenation in Transplant Donor-Recipient Pairs Using Arterial Spin Labeling and Blood Oxygen Level-Dependent Magnetic Resonance Imaging. Investigative Radiology, 2016, 51, 113-120.	6.2	38
43	The impact of hepatitis C virus donor and recipient status on longâ€term kidney transplant outcomes: University of Wisconsin experience. Clinical Transplantation, 2012, 26, 684-693.	1.6	37
44	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. Transplantation, 2007, 83, 1429-1434.	1.0	35
45	Quantitative MR Measures of Intrarenal Perfusion in the Assessment of Transplanted Kidneys. Academic Radiology, 2009, 16, 1077-1085.	2.5	34
46	Fibrogenesis in Kidney Transplantation: Potential Targets for Prevention and Therapy. Transplantation, 2009, 88, 1149-1156.	1.0	34
47	Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. Transplantation Direct, 2017, 3, e227.	1.6	34
48	Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney International, 2013, 83, 1185-1192.	5.2	33
49	Markers of Endothelial-to-Mesenchymal Transition. Journal of the American Society of Nephrology: JASN, 2016, 27, 324-332.	6.1	33
50	Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation â€" A review. Transplantation Reviews, 2016, 30, 85-91.	2.9	32
51	Renal Function and Transplantation in Liver Disease. Transplantation, 2015, 99, 1756-1764.	1.0	31
52	Recurrent Atypical Hemolytic Uremic Syndrome Associated With Factor I Mutation in a Living Related Renal Transplant Recipient. American Journal of Kidney Diseases, 2009, 53, 321-326.	1.9	29
53	Donor-Specific Antibodies in the Absence ofÂRejection Are Not a Risk Factor for Allograft Failure. Kidney International Reports, 2019, 4, 1057-1065.	0.8	29
54	Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation. Transplantation, 2019, 103, 1468-1476.	1.0	29

#	Article	IF	Citations
55	AT1R blockade reduces IFN-Î³ production in lymphocytes in vivo and in vitro. Kidney International, 2005, 67, 2134-2142.	5.2	28
56	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2008, 19, 812-824.	6.1	28
57	Posttransplant anemia: the role of sirolimus. Kidney International, 2009, 76, 376-382.	5.2	27
58	Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study. Transplant International, 2018, 31, 32-37.	1.6	27
59	Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression. World Journal of Transplantation, 2019, 9, 123-133.	1.6	27
60	Left Atrial Volume Is Associated with Inflammation and Atherosclerosis in Patients with Kidney Disease. Echocardiography, 2008, 25, 264-269.	0.9	26
61	Mycophenolic Acid May Delay Allograft Fibrosis by Inhibiting Transforming Growth Factor-Î²1-Induced Activation of Nox-2 Through the Nuclear Factor-ÎºB Pathway. Transplantation, 2010, 90, 387-393.	1.0	26
62	Metabolic Acidosis 1 Year Following Kidney Transplantation and Subsequent Cardiovascular Events and Mortality: An Observational Cohort Study. American Journal of Kidney Diseases, 2019, 73, 476-485.	1.9	26
63	Pretransplant transcriptomic signature in peripheral blood predicts early acute rejection. JCI Insight, 2019, 4, .	5.0	26
64	Role of novel biomarkers in kidney transplantation. World Journal of Transplantation, 2020, 10, 230-255.	1.6	26
65	Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney International, 2013, 83, 84-92.	5.2	25
66	Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation. American Journal of Transplantation, 2020, 20, 1513-1526.	4.7	25
67	Serum Î² 2 -microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney International, 2013, 84, 810-817.	5.2	24
68	Harald C. Ott: Clinician-scientist, Cardiothoracic Surgeon, Massachusetts General Hospital, Harvard Medical School. Transplantation, 2019, 103, 862-863.	1.0	24
69	Is Kidney Transplantation a Better State of CKD? Impact on Diagnosis and Management. Advances in Chronic Kidney Disease, 2016, 23, 287-294.	1.4	23
70	Chronic allograft injury: Mechanisms and potential treatment targets. Transplantation Reviews, 2017, 31, 1-9.	2.9	23
71	Update on nephrogenic systemic fibrosis: are we making progress?. International Journal of Dermatology, 2011, 50, 659-666.	1.0	22
72	Which is more nephrotoxic for kidney transplants: <scp>BK</scp> nephropathy or rejection?. Clinical Transplantation, 2018, 32, e13216.	1.6	22

#	Article	IF	Citations
73	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. Transplantation, 2021, 105, 648-659.	1.0	22
74	Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury. Transplantation Reviews, 2017, 31, 257-267.	2.9	21
75	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. Transplantation Proceedings, 2020, 52, 2659-2662.	0.6	21
76	Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?. Kidney International, 2020, 98, 513-514.	5.2	20
77	MR measures of renal perfusion, oxygen bioavailability and total renal blood flow in a porcine model: noninvasive regional assessment of renal function. Nephrology Dialysis Transplantation, 2012, 27, 128-135.	0.7	19
78	Hypertension guidelines: How do they apply to kidney transplant recipients. Transplantation Reviews, 2018, 32, 225-233.	2.9	19
79	FAS-MEDIATED CYTOTOXICITY IS NOT REQUIRED FOR REJECTION OF MURINE NONVASCULARIZED HETEROTOPIC CARDIAC ALLOGRAFTS1,2,3. Transplantation, 1998, 66, 1793-1801.	1.0	19
80	Mitral Annular Calcification is Associated with Reduced Left Ventricular Function and Inflammation in Patients with Chronic Kidney Disease. Journal of the American Society of Echocardiography, 2008, 21, 747-750.	2.8	18
81	Native kidney function following liver transplantation using calcineurin inhibitors: singleâ€center analysis with 20Âyears of followâ€up. Clinical Transplantation, 2013, 27, 193-202.	1.6	18
82	One-Year Serum Albumin is an Independent Predictor of Outcomes in Kidney Transplant Recipients. , 2010, 20, 392-397.		17
83	Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: From toxicogenomics to emerging biomarkers. Pharmacological Research, 2011, 64, 25-30.	7.1	17
84	Outcomes after simultaneous kidneyâ€pancreas versus pancreas after kidney transplantation in the current era. Clinical Transplantation, 2019, 33, e13732.	1.6	17
85	How Should Pancreas Transplant Rejection Be Treated?. Transplantation, 2019, 103, 1928-1934.	1.0	17
86	The Association Between Renin-Angiotensin System Blockade and Long-term Outcomes in Renal Transplant Recipients. Transplantation, 2016, 100, 1541-1549.	1.0	16
87	Evaluation of renal metabolic response to partial ureteral obstruction with hyperpolarized ¹³C MRI. NMR in Biomedicine, 2018, 31, e3846.	2.8	16
88	Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes. BMC Nephrology, 2018, 19, 332.	1.8	15
89	The feared five fungal infections in kidney transplant recipients: A singleâ€center 20â€year experience. Clinical Transplantation, 2018, 32, e13289.	1.6	15
90	Increase in proteinuria >200 mg/g after late rejection is associated with poor graft survival. Nephrology Dialysis Transplantation, 2010, 25, 1300-1306.	0.7	14

#	Article	IF	Citations
91	Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years. Kidney Diseases (Basel, Switzerland), 2018, 4, 255-261.	2.5	14
92	Sleep disorders: Serious threats among kidney transplant recipients. Transplantation Reviews, 2019, 33, 9-16.	2.9	14
93	Obesity: An Independent Predictor of Morbidity and Graft Loss after Kidney Transplantation. American Journal of Nephrology, 2020, 51, 615-623.	3.1	14
94	Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model. PLoS ONE, 2019, 14, e0211865.	2.5	13
95	Sexual concerns among kidney transplant recipients. Clinical Transplantation, 2014, 28, 1294-1302.	1.6	12
96	In Kidney Transplant Recipients With a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. Transplantation, 2016, 100, 655-661.	1.0	12
97	More Than 25 Years of Pancreas Graft Survival After Simultaneous Pancreas and Kidney Transplantation: Experience From the World's Largest Series of Long-term Survivors. Transplantation, 2020, 104, 1287-1293.	1.0	12
98	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. Kidney360, 2021, 2, 1998-2009.	2.1	12
99	Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review. Nefrologia, 2016, 36, 469-480.	0.4	11
100	Delayed graft function and acute rejection following HLA-incompatible living donor kidney transplantation. American Journal of Transplantation, 2021, 21, 1612-1621.	4.7	11
101	Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation, 2015, 99, 1785-1795.	1.0	10
102	Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients. Pharmacotherapy, 2016, 36, 823-829.	2.6	10
103	Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system. Clinical Transplantation, 2017, 31, e12895.	1.6	10
104	Incidence and Indications for Late Allograft Pancreatectomy While on Continued Immunosuppression. Transplantation, 2017, 101, 2228-2234.	1.0	10
105	<scp>BK</scp> viremia is not associated with adverse outcomes in the absence of <scp>BK</scp> nephropathy. Clinical Transplantation, 2018, 32, e13283.	1.6	10
106	Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy. Kidney International Reports, 2019, 4, 582-593.	0.8	10
107	Outcomes of Delayed Graft Function in Kidney Transplant Recipients Stratified by Histologic Biopsy Findings. Transplantation Proceedings, 2021, 53, 1462-1469.	0.6	10
108	Nox2 and Cyclosporine-Induced Renal Hypoxia. Transplantation, 2016, 100, 1198-1210.	1.0	9

#	Article	IF	Citations
109	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. Transplantation Reviews, 2020, 34, 100567.	2.9	9
110	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplantation Reviews, 2021, 35, 100649.	2.9	9
111	Higher Pretransplantation Hemoglobin A1c Is Associated With Greater Risk of Posttransplant Diabetes Mellitus. Kidney International Reports, 2017, 2, 1076-1087.	0.8	8
112	Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. Transplant International, 2018, 31, 293-301.	1.6	8
113	Nocardia infection in kidney transplant recipients: A singleâ€center experience. Transplant Infectious Disease, 2019, 21, e13192.	1.7	8
114	Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients. Transplantation, 2020, 104, 2609-2615.	1.0	8
115	Outcomes of simultaneous pancreas and kidney transplants based on preemptive transplant compared to those who were on dialysis before transplant â€“ a retrospective study. Transplant International, 2020, 33, 1106-1115.	1.6	8
116	Delayed kidney graft function in simultaneous pancreas-kidney transplant recipients is associated with early pancreas allograft failure. American Journal of Transplantation, 2020, 20, 2822-2831.	4.7	8
117	Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients. Kidney360, 2021, 2, 905-915.	2.1	8
118	Serum HSP27 is associated with medullary perfusion in kidney allografts. Journal of Nephrology, 2012, 25, 1075-1080.	2.0	7
119	The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database. Transplantation, 2019, 103, 1683-1688.	1.0	7
120	Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival. Transplantation Direct, 2019, 5, e473.	1.6	7
121	Incidence, risk factors, and outcomes of postâ€transplant erythrocytosis after kidney transplantation. Clinical Transplantation, 2021, 35, e14166.	1.6	7
122	Successful management of Tâ€cell mediated rejection in a recent kidney transplant recipient with COVIDâ€19 associated severe acute respiratory syndrome. Transplant Infectious Disease, 2021, 23, e13598.	1.7	7
123	Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile. Kidney International, 2010, 78, S15-S21.	5.2	6
124	Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides. Transplantation Direct, 2017, 3, e223.	1.6	6
125	Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Injury in Kidney Transplant Recipients During the Time of the Coronavirus Disease 2019 Pandemic. Transplantation Proceedings, 2020, 52, 2592-2595.	0.6	6
126	Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. Transplant Infectious Disease, 2020, 22, e13272.	1.7	6

#	Article	IF	Citations
127	Continuation of Peritoneal Dialysis in Adult Kidney Transplant Recipients With Delayed Graft Function. Kidney International Reports, 2021, 6, 1634-1641.	0.8	6
128	Transplant kidney biopsy for proteinuria with stable creatinine: Findings and outcomes. Clinical Transplantation, 2021, 35, e14436.	1.6	6
129	Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney360, 2021, 2, 312-324.	2.1	6
130	Disease Progression and Outcomes in Type 1 Diabetic Kidney Transplant Recipients Based on Posttransplantation CKD Staging. American Journal of Kidney Diseases, 2007, 50, 631-640.	1.9	5
131	Older kidney transplant patients experience less antibodyâ€mediated rejection: a retrospective study of patients with mild to moderate sensitization. Clinical Transplantation, 2015, 29, 1090-1097.	1.6	5
132	Cause of End-Stage Renal Disease Is Not a Risk Factor for Cytomegalovirus Infection After Kidney Transplant. Transplantation Proceedings, 2019, 51, 1810-1815.	0.6	5
133	Hospitalization Trends for Acute Kidney Injury in Kidney Transplant Recipients in the United States, 2004â€“2014. Transplantation, 2019, 103, 2405-2412.	1.0	5
134	Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transplant Infectious Disease, 2021, 23, e13561.	1.7	5
135	Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis. Transplant Infectious Disease, 2021, 23, e13702.	1.7	5
136	Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. Kidney360, 2020, 1, 389-398.	2.1	5
137	How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy. Transplantation Direct, 2022, 8, e1305.	1.6	5
138	Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients. Kidney360, 2020, 1, 1407-1418.	2.1	4
139	Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A crossâ€sectional study. Clinical Transplantation, 2020, 34, e13999.	1.6	4
140	Postâ€kidney transplant serum magnesium exhibits a Uâ€shaped association with subsequent mortality: an observational cohort study. Transplant International, 2021, 34, 1853-1861.	1.6	4
141	Non-obstructive coronary angiogram findings prior to kidney transplantation do not predict post-transplant cardiac events. Clinical Nephrology, 2020, 94, 273-280.	0.7	4
142	Contributing factors to complications and surgical success in mouse kidney transplantation. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2012, 38, 395-404.	1.5	3
143	Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells. Transplantation Direct, 2018, 4, e387.	1.6	3
144	A Single-Center Assessment of Delayed Graft Function in Recipients of Simultaneous Liver and Kidney Transplant. Progress in Transplantation, 2020, 30, 342-348.	0.7	3

#	Article	IF	Citations
145	Third-party vessel allografts in kidney and pancreas transplantation: Utilization, de novo DSAs, and outcomes. American Journal of Transplantation, 2020, 20, 3443-3450.	4.7	3
146	Incidence and Outcomes of Significant Weight Changes After Pancreas Transplant Alone. Transplantation Direct, 2020, 6, e539.	1.6	3
147	Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. Transplantation, 2021, 105, 436-442.	1.0	3
148	Post-Transplant CMV Glomerulitis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 957-959.	4.5	3
149	Association of Human Leukocyte Antigen Mismatches Between Donorâ€recipient And Donorâ€donor in Pancreas after Kidney Transplant Recipients. Transplant International, 2021, , .	1.6	3
150	Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia. Transplantation Direct, 2021, 7, e644.	1.6	3
151	Kidney complications following COVID-19 vaccination; a review of the literature. Journal of Nephropharmacology, 2022, 11, e1-e1.	0.4	3
152	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. Transplantation, 2021, Publish Ahead of Print, .	1.0	3
153	Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transplant Infectious Disease, 2022, 24, e13768.	1.7	3
154	Factors affecting sensitization following kidney allograft failure. Clinical Transplantation, 2022, 36, e14558.	1.6	3
155	The Presence of Donor-specific Antibodies Around the Time of Pancreas Graft Biopsy With Rejection Is Associated With an Increased Risk of Graft Failure. Transplantation, 2022, 106, e289-e296.	1.0	3
156	Intrathymic injection of anti-Fas monoclonal antibody prolongs murine non-vascularized cardiac allograft survival. Transplant International, 2004, 17, 301-9.	1.6	2
157	Donor-specific antibodies in kidney transplantation: the University of Wisconsin experience. Current Opinion in Organ Transplantation, 2020, 25, 543-548.	1.6	2
158	Graft Function Variability and Slope and Kidney Transplantation Outcomes. Kidney International Reports, 2021, 6, 1642-1652.	0.8	2
159	Sodium zirconium cyclosilicate use in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2151-2153.	0.7	2
160	Preâ€transplant bariatric surgery is not associated with an increased risk of infection after kidney transplant. Transplant International, 2021, 34, 1989-1991.	1.6	2
161	Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: A single-center experience. Clinical Nephrology, 2019, 91, 95-100.	0.7	2
162	Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years. Clinical Nephrology, 2020, 94, 245-251.	0.7	2

#	Article	IF	Citations
163	Kidney transplant outcomes among recipients with postâ€transplant hip or knee joint replacement surgery. Clinical Transplantation, 2021, , e14564.	1.6	2
164	Do statins delay the incidence of ESRD in diabetic patients with moderate CKD?. Journal of Nephrology, 2010, 23, 321-7.	2.0	2
165	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical Transplantation, 2019, 33, e13452.	1.6	1
166	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. Kidney International Reports, 2021, 6, 1397-1401.	0.8	1
167	Significance of Asymptomatic Pyelonephritis Found on Kidney Transplant Biopsy. Transplantation Direct, 2021, 7, e764.	1.6	1
168	Oxidized-ATP Attenuates Kidney Allograft Rejection By Inhibiting T-Cell, B-Cell, and Macrophage Activity. Kidney360, 2020, 1, 106-114.	2.1	1
169	A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma. Clinical Nephrology, 2017, 88, 40-44.	0.7	1
170	Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy. American Journal of Physiology - Renal Physiology, 2022, 322, F89-F103.	2.7	1
171	Development and Psychometric Testing of a Sexual Concerns Questionnaire for Kidney Transplant Recipients. Journal of Nursing Measurement, 2015, 23, 499-518.	0.3	0
172	B-Lymphocyte Stimulator-Deficient Rats Prevent Donor-Specific Antibody Production and Proliferation in Rodent Model. Journal of the American College of Surgeons, 2018, 227, S251.	0.5	0
173	Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients. Transplantation Direct, 2020, 6, e526.	1.6	0
174	Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors. Transplantation Reviews, 2021, 35, 100584.	2.9	0
175	FAS AND FAS-L MEDIATED CYTOTOXICITY IN ALLOGRAFT REJECTION. Transplantation, 1998, 66, S38.	1.0	0
176	COVID-19-associated glomerulopathy and high-risk APOL1 genotype; Basis for a two-hit mechanism of injury? A narrative review on recent findings. Journal of Nephropathology, 2021, 10, e11-e11.	0.2	0
177	P.131: Persistent Low Blood Pressure After Simultaneous Pancreas and Kidney Transplant Is not Associated With an Increased Risk of Allograft Loss. Transplantation, 2021, 105, S51-S51.	1.0	0
178	Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD). Clinical Transplants, 2016, 32, 135-141.	0.2	0
179	Recurrent Podocytopathy after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.15891221.	4.5	0